Aurinia Pharmaceuticals Inc (AUPH)

[Whalatane]

RMB. re your view of a buyout for " something between 12 and 18 bucks a share."
Doubt it
AUPH only added 80 patients on Lupkynis from June thru Sept Qt 2022 ....and only 50% remain on the drug after 1 yr ....latest earning report .
Lupkynis is an expensive drug and IMHO mostly prescribed for severe LN.
Lup faces significant payer ( insurer ) resistance who often require the patient to fail Benlysta first .
Co still has a lot of cash ..$376 m in latest qt ....but IMHO unlikely to find favorable reimbursement easily in the EU or UK .
Doubt any BP is interested .
Good luck
Kiwi